IL247781B - Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells - Google Patents

Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells

Info

Publication number
IL247781B
IL247781B IL24778116A IL24778116A IL247781B IL 247781 B IL247781 B IL 247781B IL 24778116 A IL24778116 A IL 24778116A IL 24778116 A IL24778116 A IL 24778116A IL 247781 B IL247781 B IL 247781B
Authority
IL
Israel
Prior art keywords
cancer
methods
hydrostatic pressure
cellular immunotherapy
high hydrostatic
Prior art date
Application number
IL24778116A
Other languages
Hebrew (he)
Other versions
IL247781A0 (en
Inventor
Bartunkova Jirina
Spisek Radek
Original Assignee
Bartunkova Jirina
Spisek Radek
Sotio As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP11172622A external-priority patent/EP2543386A1/en
Application filed by Bartunkova Jirina, Spisek Radek, Sotio As filed Critical Bartunkova Jirina
Publication of IL247781A0 publication Critical patent/IL247781A0/en
Publication of IL247781B publication Critical patent/IL247781B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL24778116A 2011-07-05 2016-09-12 Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells IL247781B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161504387P 2011-07-05 2011-07-05
EP11172622A EP2543386A1 (en) 2011-07-05 2011-07-05 Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure
PCT/EP2012/062950 WO2013004708A1 (en) 2011-07-05 2012-07-04 Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells

Publications (2)

Publication Number Publication Date
IL247781A0 IL247781A0 (en) 2016-11-30
IL247781B true IL247781B (en) 2019-11-28

Family

ID=50023029

Family Applications (2)

Application Number Title Priority Date Filing Date
IL229702A IL229702A (en) 2011-07-05 2013-11-28 Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells
IL24778116A IL247781B (en) 2011-07-05 2016-09-12 Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL229702A IL229702A (en) 2011-07-05 2013-11-28 Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells

Country Status (7)

Country Link
JP (1) JP6235085B2 (en)
CL (1) CL2013003282A1 (en)
CY (1) CY1115803T1 (en)
HR (1) HRP20141230T1 (en)
IL (2) IL229702A (en)
MX (1) MX2013013243A (en)
ZA (1) ZA201307886B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS59898B1 (en) 2011-10-17 2020-03-31 Massachusetts Inst Technology Intracellular delivery
JP6502940B2 (en) 2013-08-16 2019-04-17 マサチューセッツ インスティテュート オブ テクノロジー Selective delivery of substances to cells
SG10201903912XA (en) 2014-10-31 2019-05-30 Massachusetts Inst Technology Delivery of biomolecules to immune cells
CN107002089B (en) 2014-11-14 2021-09-07 麻省理工学院 Disruption and field-effected delivery of compounds and compositions into cells
WO2016115179A1 (en) 2015-01-12 2016-07-21 Massachusetts Institute Of Technology Gene editing through microfluidic delivery
AU2016289530B2 (en) 2015-07-09 2021-05-06 Massachusetts Institute Of Technology Delivery of materials to anucleate cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999042564A2 (en) * 1998-02-20 1999-08-26 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
US8420078B2 (en) * 2005-03-10 2013-04-16 Yeda Research And Development Co. Ltd. Methods and immunogenic cell preparations for treating antigen-associated diseases

Also Published As

Publication number Publication date
IL229702A0 (en) 2014-01-30
ZA201307886B (en) 2015-03-25
CY1115803T1 (en) 2017-01-25
MX2013013243A (en) 2014-05-30
CL2013003282A1 (en) 2014-10-10
HRP20141230T1 (en) 2015-02-13
JP6235085B2 (en) 2017-11-22
IL247781A0 (en) 2016-11-30
IL229702A (en) 2016-09-29
JP2017025066A (en) 2017-02-02

Similar Documents

Publication Publication Date Title
PL2691110T3 (en) Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells
IL288241A (en) Improved methods of cell culture for adoptive cell therapy
IL271005A (en) Improved methods of cell culture for adoptive cell therapy
IL247781A0 (en) Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells
IL231171A0 (en) Rna engineered t cells for the treatment of cancer
HK1254859A1 (en) Methods for the treatment of breast cancer
BR112013014076A2 (en) Metabolic Targeting Methods of Cancer Cells Using Chemo and Immunotherapy for Cancer Treatment
EP2614143A4 (en) Immunotherapy of cancer using genetically engineered gd2-specific t cells
IL232890A0 (en) Immunogenic treatment of cancer
GB201100180D0 (en) Tumour cell and tissue culture
EP2734214A4 (en) Targeted osmotic lysis of cancer cells
HK1202796A1 (en) Delivery system for specifically targeting cancer cells and method of use thereof
FI2547205T3 (en) Novel methods for targeting cancer stem cells
EP2736527A4 (en) Dendritic cell (dc)-vaccine therapy for pancreatic cancer
PT2547205T (en) Novel methods for targeting cancer stem cells
HK1202070A1 (en) Vaccine for tumor immunotherapy
EP2968406A4 (en) Autologous tumor lysate-loaded dendritic cell vaccine for treatment of liver cancer
WO2011109677A3 (en) Methods of increasing macropinocytosis in cancer cells
WO2012138566A9 (en) Genetic determinants of prostate and breast cancer risk
IL229242A0 (en) Allogeneic tumor cell vaccination
EP2531211A4 (en) Method for sensitizing cells to cancer therapy
EP2750691A4 (en) Srpx for treatment of cancer

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed